Latest From Oncodesign SA
Novel therapeutic strategies for Parkinson’s disease have brought a renewed sense of optimism to those researching this neurodegenerative disorder. Numerous treatment avenues are being explored, including small molecules, gene therapy, cell therapy and medical devices to stimulate nerves deep in the brain. Digital also gets a look-in, being useful for analyzing gait and other symptoms, and addressing both mental and physical issues.
A couple of years after Ipsen returned the rights to an LRRK2 Parkinson's program, Oncodesign has bagged a new partner in Servier and stands to bank up to €320m if all goes well.
J&J Innovation's spate of deals led a busy week of deal-making involving many big pharmas. Sanofi exited its inhaled insulin partnership with MannKind, Merck collaborated with Quartet and Complix, Roche partnered with and helped finance C4, and Pfizer signed an immuno-oncology combo trial agreement with Syndax.
Champions Oncology has developed TumorGraft, a novel predictive chemo-response technology that allows companies to simulate clinical trials, test anticancer drug regimens, and identify the regimens most likely to positively impact individual cancer tumors. For the clinical trial simulation capabilities alone, the technology has a market potential of $1.6 billion in the US, according to the company.
Drug Discovery Tools
- Molecular Diversity
- Synthesis Technologies, Production Processes
- Drug Discovery Tools
- Contract Research, Toxicology Testing-CRO
- Therapeutic Areas
- Western Europe
- Parent & Subsidiaries
- Oncodesign SA
- Senior Management
Philippe Genne, PhD, Pres. & CEO
Jan Hoflack, PhD, CSO
Arnaud Lafforgue, Chief Fin. & Admin. Officer
Xavier Morge, PhD, Head, Bus. Dev. & Mktg.
Alexis Denis, PhD, Head, Discovery
- Contact Info
Phone: 380 78 8260
20 Rue Jean Mazen
P.O. Box 27627 Dijon, Bourgogne, 21076
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.